Evidence map›Paper›PMID 17530299›Full record

ArticlePediatric nephrology (Berlin, Germany)2007

Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS.

Mouin G Seikaly, Nina Salhab, Bradley A Warady, Donald Stablein

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Evidence-based practice guideline for the treatment of CKD.Clinical and experimental nephrology · 2009
    Guideline
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Effectiveness and Overall Safety of NutropinAqFrontiers in endocrinology · 2021
    Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Observational
  18. The consequences of chronic kidney disease on bone metabolism and growth in children.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2012
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Mouin G SeikalyDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75235, and Children's Mercy Hospital, Kansas City, MO, USA. Mouin.Seikaly@UTSouthwestern.edu
Nina Salhab
Bradley A Warady
Donald Stablein
Children's Mercy Hospital · USChildren's Medical Center · USEmmes (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the utilization and potential benefits of recombinant human growth hormone (rhGH) in children with chronic kidney disease (CKD) and following renal transplantation in a large patient cohort. We queried the chronic renal insufficiency (CRI), dialysis, and transplant registries of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) to characterize the frequency of rhGH utilization, factors related to its usage, and the relationship between rhGH usage and catch-up growth. Data from 6,505, 5,122, and 4,478 CRI, dialysis, and transplant patients, respectively, was evaluated. Percentage utilization of rhGH 2 years after registry entry was 22%, 33%, and 3% in children with a height standard deviation score (SDS)<-1 and age<17 years (termed candidate group) in CRI, dialysis, and transplant patients, respectively. Multivariate logistic regression analysis showed that the likelihood of using rhGH was significantly correlated with age, gender, geographical region of residence and height category within the candidate group (p<0.01). The use of rhGH was associated with catch-up growth in 27%, 11%, and 25% of candidate CRI, dialysis, and transplant patients, respectively. In the candidate group, percentage catch-up growth was highest in children who were Tanner stage 1-2, who comprised 19.4%, 7.1%, and 25.5% of the CRI, dialysis, and transplant patients, respectively. Using multiple regression analysis, the estimated impact of rhGH on final adult height (age>19 years) was 0.80, 0.50, and 0.19 SDS, in CRI, dialysis, and transplant patients, respectively. Thus, rhGH can improve height gain in some children with CKD. The use of rhGH appears to be most effective in prepubertal children with CRI.

Indexed as

AdolescentBody HeightChildChild, PreschoolClinical Trials as TopicCohort StudiesFemaleHuman Growth HormoneHumansKidney Failure, ChronicKidney TransplantationLogistic ModelsMaleMultivariate AnalysisNorth AmericaRecombinant ProteinsHuman Growth HormoneRecombinant Proteins

Identifiers

PMID17530299
OpenAlexW1981914931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.